This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance.
By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinicaltrials holding great hope for the treatment of challenging and uncurable diseases.
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Syros Pharmaceuticals’ SY-5609 for the treatment of pancreatic cancer. . The Phase I clinicaltrial that is underway is assessing SY-5609 plus chemotherapy in subjects with pancreatic cancer whose disease has advanced after Folfirinox treatment.
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinicaltrials.
There is no denying that trial complexity is continuing to increase. Several factors in recent years have contributed to this rise including more complex trial designs, the rapid adoption of decentralisation stemming from the pandemic, and larger global trials. Demand planning drives trial efficiency.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinicaltrials. Clinicaltrials data for Africa Globally, research has found that 62.2% being African American, 3.4%
The war in Ukraine has had a significant impact on clinicaltrials in Europe, exacerbating supply chain delays that were already causing multiple problems even before the Covid-19 pandemic intensified the situation. The company operates globally but was founded in Ukraine. We couldn’t put people’s lives at risk.
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drugsupply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drugsupply are critical to the success of a clinicaltrial.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinicalsupply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
The ongoing chemotherapy drug shortage is a critical situation impacting cancer care in the US. The two drugs are often used in combination to treat many types of cancer, including lung, breast and prostate cancers, as well as many leukemias and lymphomas. Carlson said, “This is an unacceptable situation.
Modern software development concepts from ecommerce applications are helping eClinical applications meet the precise needs of each clinicaltrial. IRT solutions help clinicaltrial sponsors meet the complexities of patient randomization and clinicalsupply management. until the database lock of the system.
Unlike commercial pharmaceutical packaging, the primary consideration in clinicaltrial packaging is protecting the product quality and reliability for research. Finding the best clinicaltrial packaging services providers. Clinicaltrial packaging and labelling solutions.
Supply chain uncertainty is a challenge every clinicalsupply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinicaltrial designs and a lack of visibility in the supply chain. Accelerating your clinicaltrialsupply through digitalization.
Collaboration provides clinicaltrial sponsors with access to the world’s most efficient clinicalsupply processes using a single contract. As a result, global clinicalsupply and operations teams can now single source their commercial drug requirements by utilizing two best-in-class solution providers.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drugsupply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drugsupply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drugsupply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drugsupply is managed. Simply put, it’s the story of the trial.
“In collaboration with our partner, Novartis, our team continues to move at extraordinary speed from idea to bench to clinicaltrials, driven by a common desire to help patients against this devastating disease and help bring the world back closer to normalcy.” million doses of MP0420, if it is approved in Switzerland.
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01.
for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., In July 2020, the U.S.
Randomization and TrialSupply Management (RTSM) play a pivotal role in the successful execution of clinicaltrials. As the complexity of clinicaltrials continues to increase, especially with the rise of multi-center, adaptive, and decentralized trials, the need for robust RTSM systems has become more critical than ever.
company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinicaltrials. (AWS), an Amazon.com, Inc.
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinicaltrial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.
Food and Drug Administration (“FDA”) approval. Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. PharmaDrug Inc.
After backing from the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) last month, Johnson and Johnson (J&J) and Bristol Myers Squibb (BMS) scored FDA approvals for the use of their B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies as earlier line treatment options for multiple myeloma.
Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content